Search results
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda By Reuters
Investing.com· 4 days agoKeytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past...
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patents
Quartz· 4 days agoBoth companies reported quarterly earning Thursday, providing insights into how the drug...
Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda
The Wall Street Journal· 4 days agoShares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 5 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 4 days agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
WSAU Wausau· 4 days agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 4 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Proactive Investors· 5 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after...
Merck Beats on Earnings a Month After Major Drug Approval. The Stock Is Rising.
Barrons.com· 4 days agoFEATURE Sales of Merck ‘s blockbuster cancer drug Keytruda jumped 20% in the first quarter of the...
Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
Bloomberg· 4 days agoMerck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda...